IMRX

Immuneering Corp. Class A · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website immuneering.com
Employees(FY) 67
ISIN US45254E1073

Performance

-5.77%

1W

-20.11%

1M

-77.73%

3M

-71.4%

6M

-80.0%

YTD

-83.03%

1Y

Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Advanced Technical Analysis

Technical Analysis of IMRX 2024-05-10

Overview:

In analyzing the technical indicators for IMRX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...

See more ...

Recent News & Updates

2024-05-17 00:50
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment(Prnewswire)
2024-05-07 10:55
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024(Investorplace)
2024-05-07 04:05
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-05-06 04:30
Immuneering Recognizes Melanoma Awareness Month(Globenewswire)
2024-04-09 00:00
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models(Globenewswire)
2024-04-03 04:05
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference(Globenewswire)
2024-03-26 20:00
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations(Globenewswire)
2024-03-17 23:02
Immuneering (IMRX) Plummets 71% in One Week: Here's Why(Zacks)
2024-03-13 19:00
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors(Globenewswire)
2024-03-11 20:00
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors(Globenewswire)
2024-03-10 20:00
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors(Globenewswire)
2024-03-05 19:00
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning(Newsfilecorp)
2024-03-05 04:00
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024(Globenewswire)
2024-03-03 19:00
Immuneering to Participate in the Cowen 44th Annual Health Care Conference(Globenewswire)
2024-03-03 06:01
Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results(Yahoo Finance)
2024-02-29 19:00
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates(Globenewswire)
2024-02-19 19:00
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer(Globenewswire)
2024-02-14 02:45
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave(Yahoo Finance)
2024-01-31 19:00
Immuneering Announces Participation in February Investor Conferences(Globenewswire)
2023-12-11 19:00
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations(Globenewswire)
2023-11-20 03:05
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference(Globenewswire)
2023-11-09 03:05
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates(Globenewswire)
2023-10-12 04:05
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference(Globenewswire)
2023-10-04 04:05
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics(Globenewswire)
2023-09-05 20:00
Immuneering to Present at the Morgan Stanley Healthcare Conference(Yahoo Finance)
2023-08-03 04:05
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates(Yahoo Finance)
2023-08-01 18:09
Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership(Yahoo Finance)
2023-07-04 21:55
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet(Yahoo Finance)
2023-06-04 20:00
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors(Yahoo Finance)
2023-05-29 20:00
Immuneering to Present at the Jefferies Healthcare Conference(Yahoo Finance)

Page 1 of 4

previousnext